Biosimilar drugs offer a savings opportunity that we must take

Biosimilar drugs offer a savings opportunity that we must take

A dramatic increase in the prescribing of cheaper biosimilar medicines is required to enable us to afford costly new cancer and other therapies

Since 2010, the Irish health service has spent over €1 billion on two medicines alone: adalimumab (brand name: Humira) and etanercept (brand name: Enbrel). Both are complex biological medicines that are licensed to treat a variety of conditions ranging from rheumatoid arthritis and psoriatic arthropathy to inflammatory bowel disease including Crohn’s disease and ulcerative colitis.

Please Subscribe or Log in to continue reading

Subscribe Login

Independent journalism every day

With digital access you can read The Business Post whenever, wherever, and however you want.

  • Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
  • Breaking news, comment and analysis from the best Business Post writers seven days a week.
  • Live blogs of major news events.
  • Videos and podcasts from some of the industry's most respected journalists such as Michael Brennan, Susan Mitchell and Ian Guider.
  • Access to The Business Post's extensive archive​.

Related Articles

More from The Business Post